My Mum died in June 2018 after being diagnosed with Breast Cancer in 2016. Her death certificate stated that she had secondary breast cancer in her liver. This was all
Why I’m running the Great North Run for METUPUK – Sarah Lane
Emma Lawrence (née Fisher)
Emma Lawrence (née Fisher) 21.01.81 – 13.07.24 Everyone at METUPUK is incredibly saddened to hear that Emma Lawrence (née Fisher) has died at the age of 43. Emma was diagnosed
METUPUK update
METUPUK members have done amazing things in the last two years and continue to do so. Here is an update on the last two months: Founder Jo Taylor was due
My cost of living crisis – Helen Crawford
I was just 39 years old, a mother of three young girls, facing a life expectancy of two to three years post-secondary breast cancer diagnosis. My chance to see my
METUPUK at the UK Interdisciplinary Breast Cancer Symposium
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a
Dear Beth…
Hi Beth, it’s Kat here, We never met but your name is talked about so often. Whether it be an amazing thing you did, a funny story, your intellect on
Emma Saville
We met Emma as she applied to be one of the METUPUK Darker Side of Pink ladies with our campaign that started in 2021 which focused on metastatic breast cancer,
“I’m definitely living. I’m not dying yet.”
Sandy Sexton, patient advocate for METUPUK, is campaigning in Scotland on behalf of secondary/metastatic Breast Cancer patients. In October last year, after 18 months of debilitating back pain, Sandy was
The Irony of Metastatic Breast Cancer – Mary Huckle
Many of our followers on social media will remember Mary Huckle and her tireless campaigning for #metastaticbreastcancer awareness. This blog post is the last content she wrote for us, a
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)